Info

CritiTech expects pharmaceutical manufacturers to quickly recognize the superiority of CritiTech's proprietary methods for precisely manufacturing fine particle pharmaceutical compounds. The company's proprietary technology may allow pharmaceutical companies to substantially increase the probabilities of new compounds actually reaching the market place by enhancing delivery of these compounds. Additionally, CritiTech's technology can be used to extend the patent life for compounds currently being marketed by developing formulations that have improved bioavailability due to small particle size. This approach has significant potential advantages over other delivery technologies that require reformulation using "carriers" such as liposomes or other compounds. Such approaches typically require additional regulatory steps, while CritiTech's approach can potentially produce improved bioavailability without the use of such "carriers," thus avoiding the regulatory burdens and expenses that such approaches impose in new product development. By many estimates between 30% and 40% of all new chemical entities produced by pharmaceutical companies have water solubility that is low enough to render the compound unusable as a drug. CritiTech's patented technology can help manufacturers overcome this problem. A relatively small investment in the exploration of the use of CritiTech's technologies can result in a dramatic increase in the number of potential new drugs that a company can investigate.